iTeos Therapeutics Inc. (ITOS): Price and Financial Metrics


iTeos Therapeutics Inc. (ITOS): $13.19

-0.74 (-5.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ITOS POWR Grades

  • Value is the dimension where ITOS ranks best; there it ranks ahead of 86.04% of US stocks.
  • The strongest trend for ITOS is in Growth, which has been heading down over the past 177 days.
  • ITOS's current lowest rank is in the Growth metric (where it is better than 0.06% of US stocks).

ITOS Stock Summary

  • With a price/earnings ratio of 5.04, ITEOS THERAPEUTICS INC P/E ratio is greater than that of about just 12.07% of stocks in our set with positive earnings.
  • For ITOS, its debt to operating expenses ratio is greater than that reported by just 8.25% of US equities we're observing.
  • As for revenue growth, note that ITOS's revenue has grown -22.38% over the past 12 months; that beats the revenue growth of merely 8.6% of US companies in our set.
  • Stocks that are quantitatively similar to ITOS, based on their financial statements, market capitalization, and price volatility, are CYCN, ONCT, DTIL, FDMT, and PLRX.
  • Visit ITOS's SEC page to see the company's official filings. To visit the company's web site, go to www.iteostherapeutics.com.

ITOS Valuation Summary

  • ITOS's EV/EBIT ratio is 1.4; this is 78.79% lower than that of the median Healthcare stock.
  • ITOS's price/sales ratio has moved NA NA over the prior 32 months.

Below are key valuation metrics over time for ITOS.

Stock Date P/S P/B P/E EV/EBIT
ITOS 2023-03-24 1.8 0.7 5.0 1.4
ITOS 2023-03-23 1.8 0.7 4.9 1.3
ITOS 2023-03-22 1.7 0.7 4.8 1.2
ITOS 2023-03-21 1.9 0.8 5.2 1.5
ITOS 2023-03-20 1.9 0.8 5.2 1.5
ITOS 2023-03-17 1.9 0.8 5.2 1.5

ITOS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ITOS has a Quality Grade of D, ranking ahead of 24.17% of graded US stocks.
  • ITOS's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ITOS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA 44.562
2021-03-31 0 NA 60.016
2020-12-31 0 NA 15.977

ITOS Price Target

For more insight on analysts targets of ITOS, see our ITOS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $49.20 Average Broker Recommendation 1.3 (Strong Buy)

ITOS Stock Price Chart Interactive Chart >

Price chart for ITOS

ITOS Price/Volume Stats

Current price $13.19 52-week high $35.64
Prev. close $13.93 52-week low $12.52
Day low $13.15 Volume 271,100
Day high $14.15 Avg. volume 280,875
50-day MA $17.85 Dividend yield N/A
200-day MA $20.21 Market Cap 471.15M

iTeos Therapeutics Inc. (ITOS) Company Bio


iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.


ITOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ITOS Latest Social Stream


Loading social stream, please wait...

View Full ITOS Social Stream

Latest ITOS News From Around the Web

Below are the latest news stories about ITEOS THERAPEUTICS INC that investors may wish to consider to help them evaluate ITOS as an investment opportunity.

7 Dirt-Cheap Stocks Sitting in the Sweet Spot

These cheap stocks don’t just attract on the ticker tape but rather feature compelling fundamentals and analysts’ upside projections.

Josh Enomoto on InvestorPlace | March 23, 2023

Down More Than 50%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to Ignore

When stock prices fall, opportunities open up. That’s true whether we’re talking about a general market decline, or a slip in some individual stocks. However, it is crucial for investors to conduct due diligence and investigate the reasons behind the drop in price to ensure that they are making informed investment decisions. The key to success here is recognizing when a low-priced stock is fundamentally unsound or just facing tough trading conditions. Fortunately, Wall Street’s equity analysts a

Yahoo | March 23, 2023

Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper

iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders that were waiting for something to happen have been dealt a blow...

Yahoo | March 21, 2023

Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook

The latest analyst coverage could presage a bad day for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ), with the analysts...

Yahoo | March 17, 2023

ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 15, 2023

Read More 'ITOS' Stories Here

ITOS Price Returns

1-mo -21.39%
3-mo -32.46%
6-mo -30.76%
1-year -59.01%
3-year N/A
5-year N/A
YTD -32.46%
2022 -58.05%
2021 37.67%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8142 seconds.